Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Canadian Non-interventional Study of Aripiprazole Once-Monthly (AOM) Administration in Hospitalized Patients With Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder

NCT04907279 is registered in ClinicalTrials.gov with Otsuka Canada Pharmaceutical Inc. as lead sponsor.

NCT NCT04907279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04907279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Canadian Non-interventional Study of Aripiprazole Once-Monthly (AOM) Administration in Hospitalized Patients With Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder
Lead sponsor
Otsuka Canada Pharmaceutical Inc.
Phase
Observational
Overall status
Unknown status
Start date
November 1, 2021
Completion date
June 30, 2023
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, schizo affective disorder, schizophrenia